Dr. Algazi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave # M1286
Box 1270
San Francisco, CA 94143Phone+1 415-476-0624
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2007 - 2010
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2004 - 2007
- David Geffen School of Medicine at UCLAClass of 2004
Certifications & Licensure
- CA State Medical License 2006 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Start of enrollment: 2012 Jun 09
- Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets Start of enrollment: 2013 Apr 01
- Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Start of enrollment: 2013 May 01
- Join now to see all
Publications & Presentations
PubMed
- 355 citationsPembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionMartina Sanlorenzo, Igor Vujic, Adil Daud, Alain Algazi, Matthew A. Gubens
JAMA Dermatology. 2015-11-01 - 263 citationsTunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Gatien Moriceau, Willy Hugo, Aayoung Hong, Hubing Shi, Xiangju Kong
Cancer Cell. 2015-02-09 - 74 citationsContinuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert
Nature Medicine. 2020-10-05
Journal Articles
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Alain Algazi, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igo..., The New England Journal of Medicine
Press Mentions
- Leaving Lymph Nodes Intact Could Increase Efficacy of Cancer ImmunotherapyApril 12th, 2023
- Sequential-Combinatorial Regimens Can Make Treatment More Effective for People with Aggressive CancersAugust 12th, 2021
- Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and NeckMay 19th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: